Search

Your search keyword '"Wieske, Luuk"' showing total 366 results
Start Over Author "Wieske, Luuk"
366 results on '"Wieske, Luuk"'

1. Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy

Author

Michael, Milou R., Wieske, Luuk, Allen, Jeffrey A., Lunn, Michael P., Doppler, Kathrin, Tan, Cheng-Yin, Koike, Haruki, Markvardsen, Lars K., Kapoor, Mahima, Hsieh, Sung-Tsang, Nobile-Orazio, Eduardo, Jacobs, Bart C., Rajabally, Yusuf A., Basta, Ivana, Ripellino, Paolo, Querol, Luis, and Eftimov, Filip

Published
2024
Full Text
View/download PDF

2. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

Author

Stalman, Eileen W., Wieske, Luuk, Keijser, Jim B.D., van Dam, Koos P.J., Kummer, Laura Y.L., Wilbrink, Maarten F., van Kempen, Zoé L.E., Killestein, Joep, Volkers, Adriaan G., Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R. Bart, D’Haens, Geert R.A.M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederique J., Voskuyl, Alexandre E., Broens, Bo, Parra Sanchez, Agner, van Els, Cécile A.C. M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J.G.M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C.F., Onno Teng, Y.K., van Paassen, Pieter, Busch, Matthias H., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirkjan, Schreurs, Corine R.G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Cristianawati, Olvi, Brinke, Anja ten, Verstegen, Niels J.M., Zwinderman, Koos A.H., van Ham, S. Marieke, Rispens, Theo, Welkers, Matthijs R., Jonges, Marcel, Eftimov, Filip, and Kuijpers, Taco W.

Published
2024
Full Text
View/download PDF

3. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

Author

van Allaart, Renée CF., Baars, Adája E., Bekkenk, Marcel W., Bemelman, Frederike J., Boekel, Laura, Bos, Amélie V., Bosma, Angela L., Broens, Bo, Brusse, Esther, Busch, Matthias H., Cristianawati, Olvi, van Doorn, Pieter A., Elias, George, van Els, Cécile ACM., van Gils, Marit J., Goedee, H Stephan, Hijnen, Dirk Jan, Hilhorst, Marc L., Horváth, Barbara, Jallah, Papay BP., de Jongh, Rivka, Mirfazeli, Elham S., Musters, Annelie H., Keijser, Jim BD., van Kempen, Zoé LE., Killestein, Joep, Kreher, Christine, de Leeuw, Karina, van der Kooi, Anneke J., van Ouwerkerk, Lotte, van Paassen, Pieter, Cabeza, Virginia Palomares, Parra Sanchez, Agner R., Ludo van der Pol, W., Post, Nicoline F., Raaphorst, Joop, Ruiter, Annabel M., Rutgers, Abraham, Schreurs, Corine RG., Spuls, Phyllis I., Takkenberg, R Bart, Tas, Sander W., Teng, YK Onno, Vegting, Yosta, Verschuuren, Jan JGM., Voskuyl, Alexandre E., de Wit, Jelle, Wolbink, Gerrit J., van der Woude, Diane, Zwinderman, Koos AH., van den Dijssel, Jet, Duurland, Mariël C., Konijn, Veronique AL., Kummer, Laura YL., Hagen, Ruth R., Kuijper, Lisan H., Wieske, Luuk, van Dam, Koos PJ., Stalman, Eileen W., Steenhuis, Maurice, Geerdes, Dionne M., Mok, Juk Yee, Kragten, Angela HM., Menage, Charlotte, Koets, Lianne, Veldhuisen, Barbera, Verstegen, Niels JM., van der Schoot, C Ellen, van Esch, Wim JE., D'Haens, Geert RAM., Löwenberg, Mark, Volkers, Adriaan G., Rispens, Theo, Kuijpers, Taco W., Eftimov, Filip, van Gisbergen, Klaas PJM., van Ham, S Marieke, ten Brinke, Anja, and van de Sandt, Carolien E.

Published
2024
Full Text
View/download PDF

4. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

Author

van Dam, Koos P. J., Volkers, Adriaan G., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y. L., van Kempen, Zoé L. E., Killestein, Joep, Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Takkenberg, R. Bart, D’Haens, Geert R. A. M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A. C. M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C. F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, Papay B. P., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirk Jan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Keijser, Jim B. D., Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J. M., van Ham, S. Marieke, Rispens, Theo, Kuijpers, Taco W., Löwenberg, Mark, and Eftimov, Filip

Published
2023
Full Text
View/download PDF

8. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Author

de Jongh, Rivka, van de Sandt, Carolien, Kuijper, Lisan, Duurland, Mariel, Hagen, Ruth, van den Dijssel, Jet, Kreher, Christine, Bos, Amelie, Palomares Cabeza, Viriginia, Konijn, Veronique, Elias, George, Vallejo, Juan, van Gils, Marrit, Ashhurst, Tom, Nejentsev, Sergey, Mirfazeli, Elham, Boekel, Laura, Stalman, Eileen W, Wieske, Luuk, Hooijberg, Femke, van Dam, Koos P J, Besten, Yaëlle R, Kummer, Laura Y L, Steenhuis, Maurice, van Kempen, Zoé L E, Killestein, Joep, Volkers, Adriaan G, Tas, Sander W, van der Kooi, Anneke J, Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R Bart, D'Haens, Geert R A M, Spuls, Phyllis I, Bekkenk, Marcel W, Musters, Annelie H, Post, Nicoline F, Bosma, Angela L, Hilhorst, Marc L, Vegting, Yosta, Bemelman, Frederike J, Voskuyl, Alexandre E, Broens, Bo, Parra Sanchez, Agner, van Els, Cécile A C M, de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J G M, Ruiter, Annabel M, van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F, Teng, Y K Onno, van Paassen, Pieter, Busch, Matthias H, Jallah, Papay B P, Brusse, Esther, van Doorn, Pieter A, Baars, Adája E, Hijnen, Dirk Jan, Schreurs, Corine R G, van der Pol, W Ludo, Goedee, H Stephan, Vogelzang, Erik H, Leeuw, Maureen, Atiqi, Sadaf, van Vollenhoven, Ronald, Gerritsen, Martijn, van der Horst-Bruinsma, Irene E, Lems, Willem F, Nurmohamed, Mike T, Boers, Maarten, Keijzer, Sofie, Keijser, Jim, Boogaard, Arend, Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J M, Zwinderman, Koos A H, van Ham, S Marieke, Rispens, Theo, Kuijpers, Taco W, Wolbink, Gertjan, and Eftimov, Filip

Published
2022
Full Text
View/download PDF

9. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

Author

de Jongh, R., van de Sandt, C.E., Kuijper, L., Duurland, M., Hagen, R.R., van den Dijssel, J., Kreher, C., Bos, A., Palomares Cabeza, V., Konijn, V.A.L., Elias, G., Vallejo, J.G., van Gils, M.J., Ashhurst, T.M., Nejentsev, S., Mirfazeli, E.S., Wieske, Luuk, van Dam, Koos P J, Steenhuis, Maurice, Stalman, Eileen W, Kummer, Laura Y L, van Kempen, Zoé L E, Killestein, Joep, Volkers, Adriaan G, Tas, Sander W, Boekel, Laura, Wolbink, Gerrit J, van der Kooi, Anneke J, Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R Bart, D'Haens, Geert R A M, Spuls, Phyllis I, Bekkenk, Marcel W, Musters, Annelie H, Post, Nicoline F, Bosma, Angela L, Hilhorst, Marc L, Vegting, Yosta, Bemelman, Frederike J, Voskuyl, Alexandre E, Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A C M, de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J G M, Ruiter, Annabel M, van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C F, Teng, Y K Onno, van Paassen, Pieter, Busch, Matthias H, Jallah, Papay B P, Brusse, Esther, van Doorn, Pieter A, Baars, Adája E, Hijnen, Dirk Jan, Schreurs, Corine R G, van der Pol, W Ludo, Goedee, H Stephan, Keijzer, Sofie, Keijser, Jim B D, Boogaard, Arend, Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J M, Zwinderman, Koos A H, van Ham, S Marieke, Kuijpers, Taco W, Rispens, Theo, and Eftimov, Filip

Published
2022
Full Text
View/download PDF

10. Patient‐reported daily functioning after SARS‐CoV‐2 vaccinations in autoimmune neuromuscular diseases.

Author

van Dam, Koos P. J., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y. L., van der Kooi, Anneke J., Raaphorst, Joost, van de Beek, Diederik, Verschuuren, Jan J. G. M., Ruiter, Annabel M., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., van der Pol, W. Ludo, Goedee, H. Stephan, ten Brinke, Anja, van Ham, S. Marieke, Rispens, Theo, Kuijpers, Taco W., and Eftimov, Filip

Subjects
*CHRONIC inflammatory demyelinating polyradiculoneuropathy, *MOTOR neuron diseases, *NEUROMUSCULAR diseases, *CLINICAL deterioration, *IDIOPATHIC diseases
Abstract

Background and purpose: There are concerns for safety regarding SARS‐CoV‐2 vaccines for patients with autoimmune neuromuscular disease. We compared daily functioning using disease‐specific patient‐reported outcome measures (PROMs) before and after SARS‐CoV‐2 vaccinations. Methods: In this substudy of a prospective observational cohort study (Target‐to‐B!), patients with myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and idiopathic inflammatory myopathy (IIM) vaccinated against SARS‐CoV‐2 were included. Surveys of daily functioning (Myasthenia Gravis Activities of Daily Living, Inflammatory Rasch‐Built Overall Disability Scale, Multifocal Motor Neuropathy Rasch‐Built Overall Disability Scale, and Health Assessment Questionnaire–Disability Index) were sent before first vaccination and every 60 days thereafter for up to 12 months. Regression models were constructed to assess differences in PROM scores related to vaccination, compared to scores unrelated to vaccination. We also assessed the proportion of patients with deterioration of at least the minimal clinically important difference (MCID) between before first vaccination and 60 days thereafter. Results: We included 325 patients (median age = 59 years, interquartile range = 47–67, 156 [48%] female sex), of whom 137 (42%) had MG, 79 (24%) had CIDP, 43 (13%) had MMN, and 66 (20%) had IIM. PROM scores related to vaccination did not differ from scores unrelated to vaccination. In paired PROMs, MCID for deterioration was observed in three of 49 (6%) MG patients, of whom none reported a treatment change. In CIDP, MCID for deterioration was observed in eight of 29 patients (28%), of whom two of eight (25%) reported a treatment change. Conclusions: SARS‐CoV‐2 vaccination had no effect on daily functioning in patients with autoimmune neuromuscular diseases, confirming its safety in these patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

Author

Wieske, Luuk, Kummer, Laura Y. L., van Dam, Koos P. J., Stalman, Eileen W., van der Kooi, Anneke J., Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R. Bart, Volkers, Adriaan G., D’Haens, Geert R. A. M., Tas, Sander W., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Killestein, Joep, van Kempen, Zoé L. E., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, Wolbink, Gertjan, Boekel, Laura, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J. G. M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F., Teng, Y. K. Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, B. Papay, Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirkjan, Schreurs, Corine R. G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Rispens, Theo, ten Brinke, Anja, Verstegen, Niels J. M., Zwinderman, Koos A. H., van Ham, S. Marieke, Kuijpers, Taco W., and Eftimov, Filip

Published
2022
Full Text
View/download PDF

12. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Author

Boekel, Laura, Steenhuis, Maurice, Hooijberg, Femke, Besten, Yaëlle R, van Kempen, Zoé L E, Kummer, Laura Y, van Dam, Koos P J, Stalman, Eileen W, Vogelzang, Erik H, Cristianawati, Olvi, Keijzer, Sofie, Vidarsson, Gestur, Voskuyl, Alexandre E, Wieske, Luuk, Eftimov, Filip, van Vollenhoven, Ronald, Kuijpers, Taco W, van Ham, S Marieke, Tas, Sander W, Killestein, Joep, Boers, Maarten, Nurmohamed, Michael T, Rispens, Theo, and Wolbink, Gertjan

Published
2021
Full Text
View/download PDF

14. Consumptive coagulopathy is associated with a disturbed host response in patients with sepsis

Author

van Vught, Lonneke A., Uhel, Fabrice, Ding, Chao, van‘t Veer, Cees, Scicluna, Brendon P., Peters‐Sengers, Hessel, Klein Klouwenberg, Peter M.C., Nürnberg, Peter, Cremer, Olaf L., Schultz, Marcus J., van der Poll, Tom, de Beer, Friso M., Bos, Lieuwe D.J., Glas, Gerie J., Hoogendijk, Arie J., van Hooijdonk, Roosmarijn T.M., Horn, Janneke, Huson, Mischa A., Schouten, Laura R.A., Straat, Marleen, Wieske, Luuk, Wiewel, Maryse A., Witteveen, Esther, Bonten, Marc J.M., Cremer, Olaf M., Ong, David S.Y., Frencken, Jos F., Koster‐Brouwer, Maria E., van de Groep, Kirsten, and Verboom, Diana M.

Published
2021
Full Text
View/download PDF

15. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

Author

T2B! immunity against SARS-CoV-2 study group, Stalman, Eileen W., Wieske, Luuk, Keijser, Jim B.D., van Dam, Koos P.J., Kummer, Laura Y.L., Wilbrink, Maarten F., van Kempen, Zoé L.E., Killestein, Joep, Volkers, Adriaan G., Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R. Bart, D'Haens, Geert R.A.M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederique J., Voskuyl, Alexandre E., Broens, Bo, Parra Sanchez, Agner, van Els, Cécile A.C.M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J.G.M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C.F., Onno Teng, Y. K., van Paassen, Pieter, Busch, Matthias H., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirkjan, Schreurs, Corine R.G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, T2B! immunity against SARS-CoV-2 study group, Stalman, Eileen W., Wieske, Luuk, Keijser, Jim B.D., van Dam, Koos P.J., Kummer, Laura Y.L., Wilbrink, Maarten F., van Kempen, Zoé L.E., Killestein, Joep, Volkers, Adriaan G., Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R. Bart, D'Haens, Geert R.A.M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederique J., Voskuyl, Alexandre E., Broens, Bo, Parra Sanchez, Agner, van Els, Cécile A.C.M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J.G.M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C.F., Onno Teng, Y. K., van Paassen, Pieter, Busch, Matthias H., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirkjan, Schreurs, Corine R.G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, and Keijzer, Sofie

Abstract

Background: Despite impaired humoral response in patients treated with immunosuppressants (ISPs), recent studies found similar severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection compared to controls. One potential explanation is the rapid generation of humoral response on infection, but evidence is lacking. Objectives: We investigated the longitudinal dynamics of the SARS-CoV-2 antibody repertoire after SARS-CoV-2 delta and omicron breakthrough infection in patients with immune-mediated inflammatory diseases (IMIDs) receiving ISP therapy and controls. Methods: As a prospective substudy of the national Target-to-B! (T2B!) consortium, we included IMID patients receiving ISPs therapy and controls who reported SARS-CoV-2 breakthrough infection between July 1, 2021, and April 1, 2022. To get an impression of the dynamics of the antibody repertoire, 3 antibody titers of wild-type RBD, wild-type S, and omicron RBD were measured at 4 time points after SARS-CoV-2 breakthrough infection. Results: We included 302 IMID patients receiving ISPs and 178 controls. Antibody titers increased up to 28 days after breakthrough infection in both groups. However, in IMID patients receiving therapy with anti-CD20 and sphingosine-1 phosphate receptor modulators, antibody titers were considerably lower compared to controls. In the anti-TNF group, we observed slightly lower antibody titers in the early stages and a faster decline of antibodies after infection compared to controls. Breakthrough infections were mostly mild, and hospitalization was required in less than 1% of cases. Conclusions: Most ISPs do not influence the dynamics of the SARS-CoV-2 antibody repertoire and exhibit a rapid recall response with cross-reactive antibody clones toward new virus variants. However, in patients treated with anti-CD20 therapy or sphingosine-1 phosphate receptor modulators, the dynamics were greatly impaired, and to a lesser extent in those who received a

Published
2024

16. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

Author

Neurologen, Brain, Verstegen, Niels J.M., Hagen, Ruth R., Kreher, Christine, Kuijper, Lisan H., van den Dijssel, Jet, Ashhurst, Thomas, Kummer, Laura Y.L., Cabeza, Virginia Palomares, Steenhuis, Maurice, Duurland, Mariël C., de Jongh, Rivka, van der Schoot, C. Ellen, Konijn, Veronique A.L., Mul, Erik, Kedzierska, Katherine, van Dam, Koos P.J., Stalman, Eileen W., Boekel, Laura, Wolbink, Gertjan, Tas, Sander W., Killestein, Joep, Rispens, Theo, Wieske, Luuk, Kuijpers, Taco W., Eftimov, Filip, van Kempen, Zoé L.E., van Ham, S. Marieke, ten Brinke, Anja, van de Sandt, Carolien E., T2B! immunity against SARS-CoV-2 study group, Neurologen, Brain, Verstegen, Niels J.M., Hagen, Ruth R., Kreher, Christine, Kuijper, Lisan H., van den Dijssel, Jet, Ashhurst, Thomas, Kummer, Laura Y.L., Cabeza, Virginia Palomares, Steenhuis, Maurice, Duurland, Mariël C., de Jongh, Rivka, van der Schoot, C. Ellen, Konijn, Veronique A.L., Mul, Erik, Kedzierska, Katherine, van Dam, Koos P.J., Stalman, Eileen W., Boekel, Laura, Wolbink, Gertjan, Tas, Sander W., Killestein, Joep, Rispens, Theo, Wieske, Luuk, Kuijpers, Taco W., Eftimov, Filip, van Kempen, Zoé L.E., van Ham, S. Marieke, ten Brinke, Anja, van de Sandt, Carolien E., and T2B! immunity against SARS-CoV-2 study group

Published
2024

17. Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives

Author

van Doorn,Iris, Eftimov,Filip, Wieske,Luuk, van Schaik,Ivo, Verhamme,Camiel, van Doorn,Iris, Eftimov,Filip, Wieske,Luuk, van Schaik,Ivo, and Verhamme,Camiel

Abstract

Iris N van Doorn,1 Filip Eftimov,1 Luuk Wieske,1,2 Ivo N van Schaik,1,3 Camiel Verhamme1 1Department of Neurology and Clinical Neurophysiology, Amsterdam Neuroscience and University of Amsterdam, Amsterdam UMC, location AMC, the Netherlands; 2Department of Clinical Neurophysiology, Sint Antonius Hospital, Nieuwegein, the Netherlands; 3Sanquin Blood Supply Foundation, Amsterdam, the NetherlandsCorrespondence: Camiel Verhamme, Department of Neurology and Clinical Neurophysiology, Amsterdam Neuroscience and University of Amsterdam, Meibergdreef 9, Amsterdam UMC, location AMC, 1105AZ, the Netherlands, Email c.verhamme@amsterdamumc.nlAbstract: Diagnosing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) poses numerous challenges. The heterogeneous presentations of CIDP variants, its mimics, and the complexity of interpreting electrodiagnostic criteria are just a few of the many reasons for misdiagnoses. Early recognition and treatment are important to reduce the risk of irreversible axonal damage, which may lead to permanent disability. The diagnosis of CIDP is based on a combination of clinical symptoms, nerve conduction study findings that indicate demyelination, and other supportive criteria. In 2021, the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) published a revision on the most widely adopted guideline on the diagnosis and treatment of CIDP. This updated guideline now includes clinical and electrodiagnostic criteria for CIDP variants (previously termed atypical CIDP), updated supportive criteria, and sensory criteria as an integral part of the electrodiagnostic criteria. Due to its many rules and exceptions, this guideline is complex and misinterpretation of nerve conduction study findings remain common. CIDP is treatable with intravenous immunoglobulins, corticosteroids, and plasma exchange. The choice of therapy should be tailored to the individual patient’s situation, taking into account the severity of symptoms, potential

Published
2024

18. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

Author

Verstegen, Niels J.M., Hagen, Ruth R., Kreher, Christine, Kuijper, Lisan H., van den Dijssel, Jet, Ashhurst, Thomas, Kummer, Laura Y.L., Cabeza, Virginia Palomares, Steenhuis, Maurice, Duurland, Mariël C., de Jongh, Rivka, van der Schoot, C. Ellen, Konijn, Veronique A.L., Mul, Erik, Kedzierska, Katherine, van Dam, Koos P.J., Stalman, Eileen W., Boekel, Laura, Wolbink, Gertjan, Tas, Sander W., Killestein, Joep, Rispens, Theo, Wieske, Luuk, Kuijpers, Taco W., Eftimov, Filip, van Kempen, Zoé L.E., van Ham, S. Marieke, ten Brinke, Anja, van de Sandt, Carolien E., vd Kooi, A. J., Raaphorst, J., Zwinderman, A. H.Koos, Löwenberg, M., Volkers, A. G., D'Haens, G. R.A.M., Takkenberg, R. B., Hilhorst, M. L., Keijzer, S., Keijser, J. B.D., Cristianawati, O., de Leeuw, K., Ruiter, A. M., van der Woude, D., Brusse, E., van Doorn, P. A., Baars, M. A.E., Hijnen, D. J., Schreurs, C. R.G., van der Pol, W. L., de Wit, J., Verstegen, Niels J.M., Hagen, Ruth R., Kreher, Christine, Kuijper, Lisan H., van den Dijssel, Jet, Ashhurst, Thomas, Kummer, Laura Y.L., Cabeza, Virginia Palomares, Steenhuis, Maurice, Duurland, Mariël C., de Jongh, Rivka, van der Schoot, C. Ellen, Konijn, Veronique A.L., Mul, Erik, Kedzierska, Katherine, van Dam, Koos P.J., Stalman, Eileen W., Boekel, Laura, Wolbink, Gertjan, Tas, Sander W., Killestein, Joep, Rispens, Theo, Wieske, Luuk, Kuijpers, Taco W., Eftimov, Filip, van Kempen, Zoé L.E., van Ham, S. Marieke, ten Brinke, Anja, van de Sandt, Carolien E., vd Kooi, A. J., Raaphorst, J., Zwinderman, A. H.Koos, Löwenberg, M., Volkers, A. G., D'Haens, G. R.A.M., Takkenberg, R. B., Hilhorst, M. L., Keijzer, S., Keijser, J. B.D., Cristianawati, O., de Leeuw, K., Ruiter, A. M., van der Woude, D., Brusse, E., van Doorn, P. A., Baars, M. A.E., Hijnen, D. J., Schreurs, C. R.G., van der Pol, W. L., and de Wit, J.

Abstract

Background:Messenger RNA (mRNA) vaccines provide robust protection against SARS-CoV-2 in healthy individuals. However, immunity after vaccination of patients with multiple sclerosis (MS) treated with ocrelizumab (OCR), a B cell-depleting anti-CD20 monoclonal antibody, is not yet fully understood. Methods:In this study, deep immune profiling techniques were employed to investigate the immune response induced by SARS-CoV-2 mRNA vaccines in untreated patients with MS (n=21), OCR-treated patients with MS (n=57) and healthy individuals (n=30). Results:Among OCR-treated patients with MS, 63% did not produce detectable levels of antibodies (non-seroconverted), and those who did have lower spike receptor-binding domain-specific IgG responses compared with healthy individuals and untreated patients with MS. Before vaccination, no discernible immunological differences were observed between non-seroconverted and seroconverted OCR-treated patients with MS. However, non-seroconverted patients received overall more OCR infusions, had shorter intervals since their last OCR infusion and displayed higher OCR serum concentrations at the time of their initial vaccination. Following two vaccinations, non-seroconverted patients displayed smaller B cell compartments but instead exhibited more robust activation of general CD4+ and CD8+ T cell compartments, as indicated by upregulation of CD38 and HLA-DR surface expression, when compared with seroconverted patients. Conclusion:These findings highlight the importance of optimising treatment regimens when scheduling SARS-CoV-2 vaccination for OCR-treated patients with MS to maximise their humoral and cellular immune responses. This study provides valuable insights for optimising vaccination strategies in OCR-treated patients with MS, including the identification of CD38 and HLA-DR as potential markers to explore vaccine efficacy in non-seroc

Published
2024

19. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

Author

van den Dijssel, Jet, Duurland, Mariël C., Konijn, Veronique AL, Kummer, Laura YL, Hagen, Ruth R., Kuijper, Lisan H., Wieske, Luuk, van Dam, Koos PJ, Stalman, Eileen W., Steenhuis, Maurice, Geerdes, Dionne M., Mok, Juk Yee, Kragten, Angela HM, Menage, Charlotte, Koets, Lianne, Veldhuisen, Barbera, Verstegen, Niels JM, van der Schoot, C. Ellen, van Esch, Wim JE, D'Haens, Geert RAM, Löwenberg, Mark, Volkers, Adriaan G., Rispens, Theo, Kuijpers, Taco W., Eftimov, Filip, van Gisbergen, Klaas PJM, van Ham, S. Marieke, ten Brinke, Anja, van de Sandt, Carolien E., Brusse, Esther, van den Dijssel, Jet, Duurland, Mariël C., Konijn, Veronique AL, Kummer, Laura YL, Hagen, Ruth R., Kuijper, Lisan H., Wieske, Luuk, van Dam, Koos PJ, Stalman, Eileen W., Steenhuis, Maurice, Geerdes, Dionne M., Mok, Juk Yee, Kragten, Angela HM, Menage, Charlotte, Koets, Lianne, Veldhuisen, Barbera, Verstegen, Niels JM, van der Schoot, C. Ellen, van Esch, Wim JE, D'Haens, Geert RAM, Löwenberg, Mark, Volkers, Adriaan G., Rispens, Theo, Kuijpers, Taco W., Eftimov, Filip, van Gisbergen, Klaas PJM, van Ham, S. Marieke, ten Brinke, Anja, van de Sandt, Carolien E., and Brusse, Esther

Abstract

SARS-CoV-2-specific CD8+ T cells recognize conserved viral peptides and in the absence of cross-reactive antibodies form an important line of protection against emerging viral variants as they ameliorate disease severity. SARS-CoV-2 mRNA vaccines induce robust spike-specific antibody and T cell responses in healthy individuals, but their effectiveness in patients with chronic immune-mediated inflammatory disorders (IMIDs) is less well defined. These patients are often treated with systemic immunosuppressants, which may negatively affect vaccine-induced immunity. Indeed, TNF inhibitor (TNFi)-treated inflammatory bowel disease (IBD) patients display reduced ability to maintain SARS-CoV-2 antibody responses post-vaccination, yet the effects on CD8+ T cells remain unclear. Here, we analyzed the impact of IBD and TNFi treatment on mRNA-1273 vaccine-induced CD8+ T cell responses compared to healthy controls in SARS-CoV-2 experienced and inexperienced patients. CD8+ T cells were analyzed for their ability to recognize 32 SARS-CoV-2-specific epitopes, restricted by 10 common HLA class I allotypes using heterotetramer combinatorial coding. This strategy allowed in-depth ex vivo profiling of the vaccine-induced CD8+ T cell responses using phenotypic and activation markers. mRNA vaccination of TNFi-treated and untreated IBD patients induced robust spike-specific CD8+ T cell responses with a predominant central memory and activated phenotype, comparable to those in healthy controls. Prominent non-spike-specific CD8+ T cell responses were observed in SARS-CoV-2 experienced donors prior to vaccination. Non-spike-specific CD8+ T cells persisted and spike-specific CD8+ T cells notably expanded after vaccination in these patient cohorts. Our data demonstrate that regardless of TNFi treatment or prior SARS-CoV-2 infection, IBD patients benefit from vaccination by inducing a robust sp

Published
2024

20. Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy.

Author

Wieske, Luuk, Michael, Milou R., in ’t Veld, Sjors G. J. G., Visser, Allerdien, van Schaik, Ivo N., Eftimov, Filip, and Teunissen, Charlotte E.

Subjects
POLYNEUROPATHIES, CHRONIC inflammatory demyelinating polyradiculoneuropathy, CHRONIC diseases, BIOMARKERS, CELL adhesion molecules, PATTERN perception receptors
Published
2024
Full Text
View/download PDF

21. Suppressed IgG4 class switching in dupilumab‐ and TNF inhibitor‐treated patients after mRNA vaccination.

Author

Valk, Anika M., Keijser, Jim B. D., van Dam, Koos P. J., Stalman, Eileen W., Wieske, Luuk, Steenhuis, Maurice, Kummer, Laura Y. L., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Horváth, Barbara, Hijnen, Dirk‐Jan, Schreurs, Corine R. G., van Kempen, Zoé L. E., Killestein, Joep, Volkers, Adriaan G., Tas, Sander W., and Boekel, Laura

Subjects
MESSENGER RNA, VACCINATION, IMMUNOSUPPRESSIVE agents, ANTIBODY formation, METHOTREXATE
Abstract

Background: The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and is unique to humans. Although poorly understood, prolonged antigenic stimulation and IL‐4‐signaling along the T helper 2‐axis may be instrumental in IgG4 class switching. Recently, repeated SARS‐CoV‐2 mRNA vaccination has been linked to IgG4 skewing. Although widely used immunosuppressive drugs have been shown to only moderately affect humoral responses to SARS‐CoV‐2 mRNA vaccination, the effect on IgG4 switching has not been investigated. Methods: Here we study the impact of such immunosuppressive drugs, including the IL‐4 receptor‐blocking antibody dupilumab, on IgG4 skewing upon repeated SARS‐CoV‐2 mRNA vaccination. Receptor‐binding domain (RBD) specific antibody responses were longitudinally measured in 600 individuals, including patients with immune‐mediated inflammatory diseases treated with a TNF inhibitor (TNFi) and/or methotrexate (MTX), dupilumab, and healthy/untreated controls, after repeated mRNA vaccination. Results: We observed a substantial increase in the proportion of RBD‐specific IgG4 antibodies (median 21%) in healthy/untreated controls after third vaccination. This IgG4 skewing was profoundly reduced in dupilumab‐treated patients (<1%). Unexpectedly, an equally strong suppression of IgG4 skewing was observed in TNFi‐treated patients (<1%), whereas MTX caused a modest reduction (7%). RBD‐specific total IgG levels were hardly affected by these immunosuppressive drugs. Minimal skewing was observed, when primary vaccination was adenoviral vector‐based. Conclusions: Our results imply a critical role for IL‐4/IL‐13 as well as TNF in vivo IgG4 class switching. These novel findings advance our understanding of IgG4 class switch dynamics, and may benefit humoral tolerance induction strategies, treatment of IgG4 pathologies and mRNA vaccine optimization. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

Author

Palomares Cabeza, Virginia, Kummer, Laura Y.L., Wieske, Luuk, Hagen, Ruth R., Duurland, Mariel, Konijn, Veronique A.L., van Dam, Koos P.J., Stalman, Eileen W., van de Sandt, Carolien E., Boekel, Laura, Verstegen, Niels J.M., Steenhuis, Maurice, Rispens, Theo, Tas, Sander W., Wolbink, Gertjan, Killestein, Joep, Kuijpers, Taco W., van Ham, S. Marieke, Eftimov, Filip, Brinke, Anja ten, and van Kempen, Zoé L.E.

Published
2022
Full Text
View/download PDF

23. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

Author

Verstegen, Niels J M, primary, Hagen, Ruth R, additional, Kreher, Christine, additional, Kuijper, Lisan H, additional, Dijssel, Jet van den, additional, Ashhurst, Thomas, additional, Kummer, Laura Y L, additional, Palomares Cabeza, Virginia, additional, Steenhuis, Maurice, additional, Duurland, Mariël C, additional, Jongh, Rivka de, additional, Schoot, C Ellen van der, additional, Konijn, Veronique A L, additional, Mul, Erik, additional, Kedzierska, Katherine, additional, van Dam, Koos P J, additional, Stalman, Eileen W, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Tas, Sander W, additional, Killestein, Joep, additional, Rispens, Theo, additional, Wieske, Luuk, additional, Kuijpers, Taco W, additional, Eftimov, Filip, additional, van Kempen, Zoé L E, additional, van Ham, S Marieke, additional, ten Brinke, Anja, additional, and van de Sandt, Carolien E, additional

Published
2024
Full Text
View/download PDF

24. Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection

Author

Keijzer, Sofie, primary, Oskam, Nienke, additional, Ooijevaar-de Heer, Pleuni, additional, Steenhuis, Maurice, additional, Keijser, Jim B.D., additional, Wieske, Luuk, additional, van Dam, Koos P.J., additional, Stalman, Eileen W., additional, Kummer, Laura Y.L., additional, Boekel, Laura, additional, Kuijpers, Taco W., additional, ten Brinke, Anja, additional, van Ham, S. Marieke, additional, Eftimov, Filip, additional, Tas, Sander W., additional, Wolbink, Gerrit J., additional, and Rispens, Theo, additional

Published
2024
Full Text
View/download PDF

27. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod

Author

van Kempen, Zoé LE, primary, van Dam, Koos PJ, additional, Keijser, Jim BD, additional, Stalman, Eileen W, additional, Kummer, Laura YL, additional, Strijbis, Eva MM, additional, Steenhuis, Maurice, additional, ten Brinke, Anja, additional, van Ham, S. Marieke, additional, Kuijpers, Taco, additional, Rispens, Theo, additional, Eftimov, Filip, additional, Wieske, Luuk, additional, and Killestein, Joep, additional

Published
2023
Full Text
View/download PDF

29. Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort

Author

Broers, Merel C, primary, Wieske, Luuk, additional, Erdag, Ece, additional, Gürlek, Cemre, additional, Bunschoten, Carina, additional, van Doorn, Pieter A, additional, Eftimov, Filip, additional, Kuitwaard, Krista, additional, de Vries, Juna M, additional, de Wit, Marie-Claire Y, additional, Nagtzaam, Mariska MP, additional, Franken, Suzanne C, additional, Zhu, Louisa, additional, Paunovic, Manuela, additional, de Wit, Maurice, additional, Schreurs, Marco WJ, additional, Lleixà, Cinta, additional, Martín-Aguilar, Lorena, additional, Pascual-Goñi, Elba, additional, Querol, Luis, additional, Jacobs, Bart C, additional, Huizinga, Ruth, additional, and Titulaer, Maarten J, additional

Published
2023
Full Text
View/download PDF

30. Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination

Author

Valk, Anika M., primary, Keijser, Jim B.D., additional, Dam, Koos van, additional, Stalman, Eileen, additional, Wieske, Luuk, additional, Steenhuis, Maurice, additional, Kummer, Laura Y.L., additional, Spuls, Phyllis I., additional, Bekkenk, Marcel W., additional, Musters, Annelie H., additional, Post, Nicoline F., additional, Bosma, Angela L., additional, Horvath, Barbara, additional, Hijnen, DirkJan, additional, Schreurs, Corine R.G., additional, van Kempen, Zoe, additional, Killestein, Joep, additional, Volkers, Adriaan G., additional, Tas, Sander, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Keijzer, Sofie, additional, Derksen, Ninotska, additional, van Deelen, Melanie, additional, van Mierlo, Gerard, additional, Kuijpers, Taco W., additional, Eftimov, Filip, additional, Ham, Marieke van, additional, Brinke, Anja ten, additional, and Rispens, Theo, additional

Published
2023
Full Text
View/download PDF

31. Serum Contactin-1 in CIDP: A Cross-Sectional Study

Author

Wieske, Luuk, Martín-Aguilar, Lorena, Fehmi, Janev, Lleixà, Cinta, Koel-Simmelink, Marleen J.A., Chatterjee, Madhurima, van Lierop, Zoë, Killestein, Joep, Verhamme, Camiel, Querol, Luis, Rinaldi, Simon, Teunissen, Charlotte E., and Eftimov, Filip

Published
2021
Full Text
View/download PDF

34. Peripherin is a biomarker of axonal damage in peripheral nervous system disease

Author

Keddie, Stephen, primary, Smyth, Duncan, additional, Keh, Ryan Y S, additional, Chou, Michael K L, additional, Grant, Donna, additional, Surana, Sunaina, additional, Heslegrave, Amanda, additional, Zetterberg, Henrik, additional, Wieske, Luuk, additional, Michael, Milou, additional, Eftimov, Filip, additional, Bellanti, Roberto, additional, Rinaldi, Simon, additional, Hart, Melani S, additional, Petzold, Axel, additional, and Lunn, Michael P, additional

Published
2023
Full Text
View/download PDF

35. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study

Author

de Beer, Friso M., Bos, Lieuwe D.J., Frencken, Jos F., Koster-Brouwer, Maria E., van de Groep, Kirsten, Verboom, Diana M., Glas, Gerie J., van Hooijdonk, Roosmarijn T.M., Hoogendijk, Arie J., Huson, Mischa A., Klouwenberg, Peter M. Klein, Ong, David S.Y., Schouten, Laura R.A., Straat, Marleen, Witteveen, Esther, Wieske, Luuk, Scicluna, Brendon P, van Vught, Lonneke A, Zwinderman, Aeilko H, Wiewel, Maryse A, Davenport, Emma E, Burnham, Katie L, Nürnberg, Peter, Schultz, Marcus J, Horn, Janneke, Cremer, Olaf L, Bonten, Marc J, Hinds, Charles J, Wong, Hector R, Knight, Julian C, and van der Poll, Tom

Published
2017
Full Text
View/download PDF

36. Gut barrier dysfunction and the risk of ICU-acquired bacteremia- a case–control study.

Author

Varkila, Meri R. J., Verboom, Diana M., Derde, Lennie P. G., van der Poll, Tom, Bonten, Marc J. M., Cremer, Olaf L., de Beer, Friso M., Bos, Lieuwe D. J., Glas, Gerie J., Hoogendijk, Arie J., van Hooijdonk, Roosmarijn T. M., Horn, Janneke, Huson, Mischa A., Juffermans, Nicole P., Schouten, Laura R. A., Scicluna, Brendon, Schultz, Marcus J., Straat, Marleen, van Vught, Lonneke A., and Wieske, Luuk

Subjects
SKIN microbiology, CROSS infection, GUT microbiome, BACTEREMIA, BLOODBORNE infections, CATHETER-related infections, DESCRIPTIVE statistics, ODDS ratio, INTENSIVE care units, CASE-control method, CONFIDENCE intervals, BIOMARKERS
Abstract

Background: Impaired intestinal barrier function can enable passage of enteric microorganisms into the bloodstream and lead to nosocomial bloodstream infections during critical illness. We aimed to determine the relative importance of gut translocation as a source for ICU-acquired enterococcal bacteremia of unknown origin. Methods: We conducted a nested case–control study in two mixed medical-surgical tertiary ICUs in the Netherlands among patients enrolled between 2011 and 2018. We selected 72 cases with ICU-acquired bacteremia due to enterococci (which are known gastrointestinal tract commensals) and 137 matched controls with bacteremia due to coagulase-negative staphylococci (CoNS) (which are of non-intestinal origin). We measured intestinal fatty acid-binding protein, trefoil factor-3, and citrulline 48 h before bacteremia onset. A composite measure for Gut Barrier Injury (GBI) was calculated as the sum of standardized z-scores for each biomarker plus a clinical gastrointestinal failure score. Results: No single biomarker yielded statistically significant differences between cases and controls. Median composite GBI was higher in cases than in controls (0.58, IQR − 0.36–1.69 vs. 0.32, IQR − 0.53–1.57, p = 0.33) and higher composite measures of GBI correlated with higher disease severity and ICU mortality (p < 0.001). In multivariable analysis, higher composite GBI was not significantly associated with increased occurrence of enterococcal bacteremia relative to CoNS bacteremia (adjusted OR 1.12 95% CI 0.93–1.34, p = 0.22). Conclusions: We could not demonstrate an association between biomarkers of gastrointestinal barrier dysfunction and an increased occurrence of bacteremia due to gut compared to skin flora during critical illness, suggesting against bacterial translocation as a major vector for acquisition of nosocomial bloodstream infections in the ICU. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.

Author

van Kempen, Zoé LE, van Dam, Koos PJ, Keijser, Jim BD, Stalman, Eileen W, Kummer, Laura YL, Strijbis, Eva MM, Steenhuis, Maurice, ten Brinke, Anja, van Ham, S. Marieke, Kuijpers, Taco, Rispens, Theo, Eftimov, Filip, Wieske, Luuk, and Killestein, Joep

Subjects
HUMORAL immunity, SARS-CoV-2 Omicron variant, SARS-CoV-2, VACCINATION, FINGOLIMOD
Abstract

Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear. Methods: Prospective study in 60 MS patients on fingolimod measuring humoral responses after up to four vaccinations and 8 months after fourth vaccination. Results: Anti-WH1 antibody titers increased with each additional vaccination. At long-term follow-up titers increased further and most patients developed new humoral responses against the BA.1 omicron variant. Conclusion: Repeated SARS-CoV-2 vaccinations boost humoral immunity and, probably together with SARS-CoV-2 infections, induce humoral responses on the long-term in almost all patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort.

Author

Broers, Merel C., Wieske, Luuk, Erdag, Ece, Gürlek, Cemre, Bunschoten, Carina, van Doorn, Pieter A., Eftimov, Filip, Kuitwaard, Krista, de Vries, Juna M., de Wit, Marie-Claire Y., Nagtzaam, Mariska M. P., Franken, Suzanne C., Zhu, Louisa, Paunovic, Manuela, de Wit, Maurice, Schreurs, Marco W. J., Lleixà, Cinta, Martín-Aguilar, Lorena, Pascual-Goñi, Elba, and Querol, Luis

Published
2024
Full Text
View/download PDF

40. Long-term tactile hypersensitivity after nerve crush injury in mice is characterized by the persistence of intact sensory axons

Author

Kim, Hyoung Woo, primary, Shim, Sang Wook, additional, Zhao, Anna Mae, additional, Roh, Dahee, additional, Han, Hye Min, additional, Middleton, Steven J., additional, Kim, Wheedong, additional, Chung, Sena, additional, Johnson, Errin, additional, Prentice, John, additional, Tacon, Mike, additional, Koel-Simmelink, Marleen J.A., additional, Wieske, Luuk, additional, Teunissen, Charlotte E., additional, Bae, Yong Chul, additional, Bennett, David L.H., additional, Rinaldi, Simon, additional, Davies, Alexander J., additional, and Oh, Seog Bae, additional

Published
2023
Full Text
View/download PDF

41. Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

Author

Neurologen, Brain, van Dam, Koos P.J., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y.L., Roosen, Jesse, van Kempen, Zoé L.E., Killestein, Joep, Volkers, Adriaan G., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R. Bart, D'Haens, Geert R.A.M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A.C.M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J.G.M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C.F., Teng, Y. K.Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, Papay B.P., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirk Jan, Schreurs, Corine R.G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Keijser, Jim B.D., the T2B! Immunity against SARS-CoV-2 study group, Neurologen, Brain, van Dam, Koos P.J., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y.L., Roosen, Jesse, van Kempen, Zoé L.E., Killestein, Joep, Volkers, Adriaan G., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R. Bart, D'Haens, Geert R.A.M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A.C.M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J.G.M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C.F., Teng, Y. K.Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, Papay B.P., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirk Jan, Schreurs, Corine R.G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Keijser, Jim B.D., and the T2B! Immunity against SARS-CoV-2 study group

Published
2023

42. SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Author

Neurologen, Brain, Baars, Adája E., Kuitwaard, Krista, De Koning, Laura C., Luijten, Linda W.G., Kok, W. Maaike, Eftimov, Filip, Wieske, Luuk, Goedee, H. Stephan, Van Der Pol, W. Ludo, Blomkwist-Markens, Patricia H., Horemans, Anja M.C., Jacobs, Bart C., Van Doorn, Pieter A., Neurologen, Brain, Baars, Adája E., Kuitwaard, Krista, De Koning, Laura C., Luijten, Linda W.G., Kok, W. Maaike, Eftimov, Filip, Wieske, Luuk, Goedee, H. Stephan, Van Der Pol, W. Ludo, Blomkwist-Markens, Patricia H., Horemans, Anja M.C., Jacobs, Bart C., and Van Doorn, Pieter A.

Published
2023

43. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases:long-term humoral immune responses and effects on disease activity

Author

van Dam, Koos P.J., Volkers, Adriaan G., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y.L., van Kempen, Zoé L.E., Killestein, Joep, Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Takkenberg, R. Bart, D’Haens, Geert R.A.M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A.C.M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J.G.M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C.F., Teng, Y. K.Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, Papay B.P., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirk Jan, Schreurs, Corine R.G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Keijser, Jim B.D., Cristianawati, Olvi, Eftimov, Filip, van Dam, Koos P.J., Volkers, Adriaan G., Wieske, Luuk, Stalman, Eileen W., Kummer, Laura Y.L., van Kempen, Zoé L.E., Killestein, Joep, Tas, Sander W., Boekel, Laura, Wolbink, Gerrit J., van der Kooi, Anneke J., Raaphorst, Joost, Takkenberg, R. Bart, D’Haens, Geert R.A.M., Spuls, Phyllis I., Bekkenk, Marcel W., Musters, Annelie H., Post, Nicoline F., Bosma, Angela L., Hilhorst, Marc L., Vegting, Yosta, Bemelman, Frederike J., Voskuyl, Alexandre E., Broens, Bo, Sanchez, Agner Parra, van Els, Cécile A.C.M., de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J.G.M., Ruiter, Annabel M., van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Renée C.F., Teng, Y. K.Onno, van Paassen, Pieter, Busch, Matthias H., Jallah, Papay B.P., Brusse, Esther, van Doorn, Pieter A., Baars, Adája E., Hijnen, Dirk Jan, Schreurs, Corine R.G., van der Pol, W. Ludo, Goedee, H. Stephan, Steenhuis, Maurice, Keijzer, Sofie, Keijser, Jim B.D., Cristianawati, Olvi, and Eftimov, Filip

Abstract

Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term humoral immune responses against SARS-CoV-2 and increased disease activity after a primary SARS-CoV-2 infection in unvaccinated IMID patients on ISPs. Methods: IMID patients on active treatment with ISPs and controls (i.e. IMID patients not on ISP and healthy controls) with a confirmed SARS-CoV-2 infection before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical data on infections and increased disease activity were registered using electronic surveys and health records. A serum sample was collected before first vaccination to measure SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies. Results: In total, 193 IMID patients on ISP and 113 controls were included. Serum samples from 185 participants were available, with a median time of 173 days between infection and sample collection. The rate of seropositive IMID patients on ISPs was 78% compared to 100% in controls (p < 0.001). Seropositivity rates were lowest in patients on anti-CD20 (40.0%) and anti-tumor necrosis factor (TNF) agents (60.5%), as compared to other ISPs (p < 0.001 and p < 0.001, respectively). Increased disease activity after infection was reported by 68 of 260 patients (26.2%; 95% CI 21.2–31.8%), leading to ISP intensification in 6 out of these 68 patients (8.8%). Conclusion: IMID patients using ISPs showed reduced long-term humoral immune responses after primary SARS-CoV-2 infection, which was mainly attributed to treatment with anti-CD20 and anti-TNF agents. Increased disease activity after SARS-CoV-2 infection was reported commonly, but was mostly mild. Trial registration: NL74974.018.20, Trial ID: NL8900. Register

Published
2023

44. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study

Author

Schouten, Laura R., van Kaam, Anton H., Kohse, Franziska, Veltkamp, Floor, Bos, Lieuwe D., de Beer, Friso M., van Hooijdonk, Roosmarijn T., Horn, Janneke, Straat, Marleen, Witteveen, Esther, Glas, Gerie J., Wieske, Luuk, van Vught, Lonneke A., Wiewel, Maryse A., Ingelse, Sarah A., Cortjens, Bart, van Woensel, Job B., Bos, Albert P., Walther, Thomas, Schultz, Marcus J., Wösten-van Asperen, Roelie M., and for the MARS consortium

Published
2019
Full Text
View/download PDF

45. Long-term tactile hypersensitivity after nerve crush injury in mice is characterized by the persistence of intact sensory axons.

Author

Hyoung Woo Kim, Sang Wook Shim, Zhao, Anna Mae, Dahee Roh, Hye Min Han, Middleton, Steven J., Wheedong Kim, Chung, Sena, Johnson, Errin, Prentice, John, Tacon, Mike, Koel-Simmelink, Marleen J. A., Wieske, Luuk, Teunissen, Charlotte E., Yong Chul Bae, Bennett, David L. H., Rinaldi, Simon, Davies, Alexander J., and Seog Bae Oh

Published
2023
Full Text
View/download PDF

46. Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis

Author

Fehmi, Janev, primary, Davies, Alexander J., additional, Antonelou, Marilina, additional, Keddie, Stephen, additional, Pikkupeura, Sonja, additional, Querol, Luis, additional, Delmont, Emilien, additional, Cortese, Andrea, additional, Franciotta, Diego, additional, Persson, Staffan, additional, Barratt, Jonathan, additional, Pepper, Ruth, additional, Farinha, Filipa, additional, Rahman, Anisur, additional, Canetti, Diana, additional, Gilbertson, Janet A., additional, Rendell, Nigel B., additional, Radunovic, Aleksandar, additional, Minton, Thomas, additional, Fuller, Geraint, additional, Murphy, Sinead M., additional, Carr, Aisling S., additional, Reilly, Mary R., additional, Eftimov, Filip, additional, Wieske, Luuk, additional, Teunissen, Charlotte E., additional, Roberts, Ian S. D., additional, Ashman, Neil, additional, Salama, Alan D., additional, and Rinaldi, Simon, additional

Published
2023
Full Text
View/download PDF

47. Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

Author

van Dam, Koos P.J., primary, Wieske, Luuk, additional, Stalman, Eileen W., additional, Kummer, Laura Y.L., additional, Roosen, Jesse, additional, van Kempen, Zoé L.E., additional, Killestein, Joep, additional, Volkers, Adriaan G., additional, Boekel, Laura, additional, Wolbink, Gerrit J., additional, van der Kooi, Anneke J., additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, R. Bart, additional, D'Haens, Geert R.A.M., additional, Spuls, Phyllis I., additional, Bekkenk, Marcel W., additional, Musters, Annelie H., additional, Post, Nicoline F., additional, Bosma, Angela L., additional, Hilhorst, Marc L., additional, Vegting, Yosta, additional, Bemelman, Frederike J., additional, Voskuyl, Alexandre E., additional, Broens, Bo, additional, Sanchez, Agner Parra, additional, van Els, Cécile A.C.M., additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J.G.M., additional, Ruiter, Annabel M., additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Renée C.F., additional, Teng, Y.K. Onno, additional, van Paassen, Pieter, additional, Busch, Matthias H., additional, Jallah, Papay B.P., additional, Brusse, Esther, additional, van Doorn, Pieter A., additional, Baars, Adája E., additional, Hijnen, Dirk Jan, additional, Schreurs, Corine R.G., additional, van der Pol, W.Ludo, additional, Goedee, H. Stephan, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Keijser, Jim B.D., additional, Cristianawati, Olvi, additional, Rispens, Theo, additional, Brinke, Anja ten, additional, Verstegen, Niels J.M., additional, Marieke van Ham, S., additional, Tas, Sander W., additional, Kuijpers, Taco W., additional, and Eftimov, Filip, additional

Published
2023
Full Text
View/download PDF

48. Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Author

Wieske, Luuk, primary, Stalman, Eileen W, additional, van Dam, P J Koos, additional, Kummer, Laura Y, additional, Steenhuis, Maurice, additional, van Kempen, Zoe L E, additional, Killestein, Joep, additional, Volkers, Adriaan G, additional, Tas, Sander W, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Van der Kooi, Anneke, additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, Bart, additional, D’Haens, Geert R A M, additional, Spuls, Phyllis I, additional, Bekkenk, Marcel W, additional, Musters, Annelie H, additional, Post, Nicoline F, additional, Bosma, Angela L, additional, Hilhorst, Marc L, additional, Vegting, Yosta, additional, Bemelman, Frederique J, additional, Voskuyl, Alexandre, additional, Broens, Bo, additional, Parra Sanchez, Agner, additional, van Els, Cécile A C M, additional, Wit, Jelle De, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J G M, additional, Ruiter, Annabel M, additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Cornelia F, additional, Teng, Y K Onno, additional, van Paassen, Pieter, additional, Busch, Matthias H, additional, Jallah, Papay B P, additional, Brusse, Esther, additional, van Doorn, Pieter A, additional, Baars, Adája Elisabeth, additional, Hijnen, Dirkjan, additional, Schreurs, Corine R G, additional, Van der Pol, W Ludo, additional, Goedee, H Stephan, additional, Keijzer, Sofie, additional, Keijser, Jim, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels J M, additional, Zwinderman, Koos A H, additional, van Ham, S Marieke, additional, Kuijpers, Taco W, additional, Rispens, Theo, additional, and Eftimov, Filip, additional

Published
2023
Full Text
View/download PDF

49. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

Author

Dam, Koos van, primary, Volkers, Adriaan, additional, Wieske, Luuk, additional, Stalman, Eileen, additional, Kummer, Laura, additional, kempen, Zoe van, additional, Killestein, Joep, additional, Tas, Sander, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, Kooi, Anneke van der, additional, Raaphorst, Joost, additional, Takkenberg, Bart, additional, D'Haens, Geert, additional, Spuls, Phyllis, additional, Bekkenk, Marcel, additional, Musters, Annelie, additional, Post, Nicoline, additional, Bosma, Angela, additional, Hilhorst, Marc, additional, Vegting, Yosta, additional, Bemelman, Frederike, additional, Voskuyl, Alexandre, additional, Broens, Bo, additional, Sanchez, Agner Parra, additional, Els, Cecile van, additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horvath, Barbara, additional, Verschuuren, Jan, additional, Ruiter, Annabel, additional, Ouwerkerk, Lotte van, additional, Woude, Diane van der, additional, Allaart, Renee, additional, Teng, Onno, additional, Paassen, Pieter van, additional, Busch, Matthias, additional, Jallah, Papay, additional, Brusse, Esther, additional, Doorn, Pieter van, additional, Baars, Adaja, additional, Hijnen, DirkJan, additional, Schreurs, Corine, additional, Pol, Ludo van der, additional, Goedee, Stephan, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Keijser, Jim, additional, Cristianawati, Olvi, additional, Brinke, Anja ten, additional, Verstegen, Niels, additional, Ham, Marieke van, additional, Rispens, Theo, additional, Kuijpers, Taco, additional, Lowenberg, Mark, additional, and Eftimov, Filip, additional

Published
2023
Full Text
View/download PDF

50. Longitudinal Dynamics of the SARS-CoV-2 Antibody Repertoire after SARS-CoV-2 Delta and Omicron Breakthrough Infections in Patients with Immune-Mediated Inflammatory Diseases

Author

Stalman, Eileen, primary, Wieske, Luuk, additional, Keijser, Jim, additional, van Dam, Koos, additional, Kummer, Laura, additional, Wilbrink, Maarten F., additional, van Kempen, Zoé, additional, Killestein, Joep, additional, Volkers, Adriaan G., additional, Tas, Sander, additional, Boekel, Laura, additional, Wolbink, Gertjan, additional, van der Kooi, Anneke J., additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, R. Bart, additional, D&apos;Haens, Geert R.A.M., additional, Spuls, Phyllis I., additional, Bekkenk, Marcel W., additional, Musters, Annelie H., additional, Post, Nicoline F., additional, Bosma, Angela L., additional, Hilhorst, Marc L., additional, Vegting, Yosta, additional, Bemelman, Frederike J., additional, Voskuyl, Alexandre, additional, Broens, Bo, additional, Sanchez, Agner Parra, additional, van Els, Cecile, additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J.G.M., additional, Ruiter, Annabel M., additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Cornelia F., additional, Teng, Onno YK, additional, van Paassen, Pieter, additional, Busch, Matthias, additional, Brusse, Esther, additional, van Doorn, Pieter, additional, Baars, Adája E., additional, Hijnen, Dirk Jan, additional, Schreurs, Corine R.G., additional, van der Pol, Ludo, additional, Goedee, H. Stephan, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels, additional, Zwinderman, Aeilko H., additional, van Ham, Marieke, additional, Rispens, Theo, additional, Welkers, Matthijs R.A., additional, Jonges, Marcel, additional, Eftimov, Filip, additional, and Kuijpers, Taco, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results